FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Video

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.

Related Videos
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Don S. Dizon, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Patrick I. Borgen, MD
Henry Kuerer, MD, PhD, FACS, CMQ